Evidence map›Paper›PMID 32597548›Full record

Trial reportJournal of diabetes investigation2021

Randomized trial of an intensified, multifactorial intervention in patients with advanced-stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan).

Kenichi Shikata, Masakazu Haneda, Toshiharu Ninomiya, Daisuke Koya, Yoshiki Suzuki, Daisuke Suzuki, Hitoshi Ishida, Hiroaki Akai, Yasuhiko Tomino, Takashi Uzu and 6 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 5 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 5 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Education programmes for people with chronic kidney disease and diabetes.The Cochrane database of systematic reviews · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Updates on dyslipidemia in patients with diabetes.Journal of diabetes investigation · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Renoprotective Effects of DPP-4 Inhibitors.Antioxidants (Basel, Switzerland) · 2021
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 1 country.

Kenichi ShikataCenter for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.ORCID https://orcid.org/0000-0003-3598-636X
Masakazu HanedaDivision of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Toshiharu NinomiyaDepartment of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0003-1345-9032
Daisuke KoyaDepartment of Diabetology & Endocrinology, Kanazawa Medical University, Ishikawa, Japan.ORCID https://orcid.org/0000-0003-2711-1539
Yoshiki SuzukiHealth Administration Center, Niigata University, Niigata, Japan.
Daisuke SuzukiSuzuki Diabetes Clinic, Kanagawa, Japan.
Hitoshi IshidaResearch Center for Health Care, Nagahama City Hospital, Shiga, Japan.
Hiroaki AkaiDivision of Metabolism and Diabetes, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Yasuhiko TominoDivision of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.
Takashi UzuDivision of Nephrology, Department of Medicine, Nippon Life Hospital, Osaka, Japan.
Motonobu NishimuraDepartment of Diabetes and Endocrinology, National Hospital Organization Chiba-East National Hospital, Chiba, Japan.
Shiro MaedaDepartment of Advanced Genomic and Laboratory Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Daisuke OgawaOkayama Diabetes and Neurology Clinic, Okayama, Japan.
Satoshi MiyamotoCenter for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
Hirofumi MakinoOkayama University, Okayama, Japan.
Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan) collaborative group
Okayama University Hospital · JPAsahikawa Medical University · JPChiba East Hospital · JPJuntendo University · JPKanazawa Medical University · JPKyushu University · JPNagahama City Hospital · JPNiigata University · JPNippon Medical School Hospital · JPOkayama Psychiatric Medical Center · JPOkayama University · JPSuzuki (Japan) · JPTohoku Medical and Pharmaceutical University · JPUniversity of the Ryukyus · JP

Funding

Asahi Kasei PharmaAstellasAstraZenecaBayerBoehringer IngelheimChugaiDaiichi SankyoEizaiEli LillyKowa PharmaceuticalMinistry of Health, Labor and Welfare of Japan 200624010BMitsubishi Tanabe PharmaMSDNovartis PharmaOkayama Medical FoundationOtsukaSanofi AventisSanwa KagakuSumitomo Dainippon PharmaTakedaTeijin PharmaTerumo
6 · The paper itself

Abstract

AIMS/

introductionWe evaluated the efficacy of multifactorial intensive treatment (IT) on renal outcomes in patients with type 2 diabetes and advanced-stage diabetic kidney disease (DKD). MATERIALS AND

methodsThe Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan) is a multicenter, open-label, randomized controlled trial with a 5-year follow-up period. We randomly assigned 164 patients with advanced-stage diabetic kidney disease (urinary albumin-to-creatinine ratio ≥300 mg/g creatinine, serum creatinine level 1.2-2.5 mg/dL in men and 1.0-2.5 mg/dL in women) to receive either IT or conventional treatment. The primary composite outcome was end-stage kidney failure, doubling of serum creatinine or death from any cause, which was assessed in the intention-to-treat population.

resultsThe IT tended to reduce the risk of primary end-points as compared with conventional treatment, but the difference between treatment groups did not reach the statistically significant level (hazard ratio 0.69, 95% confidence interval 0.43-1.11; P = 0.13). Meanwhile, the decrease in serum low-density lipoprotein cholesterol level and the use of statin were significantly associated with the decrease in primary outcome (hazard ratio 1.14; 95% confidence interval 1.05-1.23, P < 0.001 and hazard ratio 0.53, 95% confidence interval 0.28-0.998, P < 0.05, respectively). The incidence of adverse events was not different between treatment groups.

conclusionsThe risk of kidney events tended to decrease by IT, although it was not statistically significant. Lipid control using statin was associated with a lower risk of adverse kidney events. Further follow-up study might show the effect of IT in patients with advanced diabetic kidney disease.

Indexed as

BiomarkersBlood GlucoseDiabetes Mellitus, Type 2Diabetic NephropathiesEarly Medical InterventionFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisProspective StudiesRemission InductionBiomarkersBlood GlucoseDiabetic kidney diseaseDiabetic nephropathyDiabetic Nephropathy Remission and Regression Team Trial in Japan

Identifiers

PMID32597548
PMCPMC7858124
OpenAlexW3037046335

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.